A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
A Real-world Study of the Efficacy and Safety of Amlotinib for the Treatment of HER2-negative Advanced Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jiuwei Cui
- Phone Number: 15843073215
- Email: jdyycjw@163.com
Study Contact Backup
- Name: Zheng Lv
- Phone Number: 15804301705
- Email: lvz@jlu.edu.cn
Study Locations
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The first Affiliated Hospital of Jilin University
-
Principal Investigator:
- xu sun
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Imaging or tissue/cell puncture, etc. confirmed recurrent, metastatic breast cancer
- Pathologically confirmed HER-2 negative
- Application of amlotinib treatment until disease progression or toxicity intolerable, or voluntarily give up the continuation of amlotinib treatment,amlotinib application for at least 2 cycles
- The clinical data are basically complete
Exclusion criteria:
- Patients receiving local treatment means such as surgery and radiotherapy
- Patients with combined second primary breast cancer and other primary malignant tumors
- Patients with symptomatic brain metastases
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: Incorporation January 2021 through November 2023
|
Progression-FreeSurvival
|
Incorporation January 2021 through November 2023
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-KS-151
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.